Correlating EGFR Expression with Receptor-Binding Properties and Internalization of ^sup 64^Cu-DOTA-...
Correlating EGFR Expression with Receptor-Binding Properties and Internalization of ^sup 64^Cu-DOTA-Cetuximab in 5 Cervical Cancer Cell Lines
About this item
Full title
Author / Creator
Publisher
New York: Society of Nuclear Medicine
Journal title
Language
English
Formats
Publication information
Publisher
New York: Society of Nuclear Medicine
Subjects
More information
Scope and Contents
Contents
The anti-epidermal growth factor receptor (anti-EGFR) antibody cetuximab is clinically approved for the treatment of EGFR-expressing metastatic colorectal cancer and advanced head and neck cancer. Overexpression of EGFR has also been found in more than 70% of carcinomas of the cervix. The overall goal of this study was to determine whether ^sup 64^...
Alternative Titles
Full title
Correlating EGFR Expression with Receptor-Binding Properties and Internalization of ^sup 64^Cu-DOTA-Cetuximab in 5 Cervical Cancer Cell Lines
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_219284784
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_219284784
Other Identifiers
ISSN
0161-5505
E-ISSN
1535-5667
